CGM Medication-Driven Changes: How GLP-1s, Metformin, SGLT2s, and Other Drugs Shift Your Continuous Glucose Monitor Readings

What CGM Actually Measures and Why Medications Matter

A CGM sensor measures interstitial fluid glucose, not venous plasma glucose directly. The two values track within roughly 10 to 15 mg/dL under stable conditions, but the lag can stretch to 20 minutes during rapid glucose flux, exactly the window when fast-acting medications act. That lag is not a flaw; it is a physiological reality that clinicians must factor in when reading drug-response curves on a CGM trace.

The clinical evidence for CGM as a medication-management tool is now substantial. The DIAMOND trial (N=158) demonstrated that adults with type 2 diabetes using CGM alongside multiple daily injections reduced A1C by 1.0% more than those using self-monitored blood glucose alone over 24 weeks (1). That improvement was driven entirely by the real-time feedback loop that CGM creates between a drug dose and a visible glucose curve.

How Interstitial Lag Shapes Drug-Response Interpretation

When a patient takes a GLP-1 receptor agonist subcutaneously, the peak plasma concentration arrives hours later. But once the drug is active, postprandial glucose excursions shrink within days to weeks. On a CGM trace, that shows up as a flattening of the post-meal spike rather than a shift in fasting baseline. Clinicians who look only at fasting CGM values will miss the signal.

Insulin, by contrast, acts within 15 minutes (lispro, aspart) to 4 hours (glargine). Its CGM fingerprint is a rapid downslope. A CV that drops below 36% after starting basal insulin is a reliable sign that the dose is working; a CV that stays above 40% suggests the regimen needs adjustment (2).

The Three CGM Metrics That Matter Most for Medication Monitoring

Clinicians tracking medication response on CGM should anchor to three numbers:

• Time in range (TIR): percentage of readings between 70 and 180 mg/dL. The ADA Standards of Care 2024 target is above 70% for most adults with diabetes (3).
• Mean sensor glucose (MSG): the CGM-derived average. An MSG below 154 mg/dL approximates an A1C below 7%.
• Coefficient of variation (CV): standard deviation divided by mean, expressed as a percentage. The Advanced Technologies and Treatments for Diabetes (ATTD) 2023 consensus sets a safe glycemic variability target at CV below 36% (2).

GLP-1 Receptor Agonists: The Most Visible CGM Effect of Any Oral or Injectable Drug Class

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide, dulaglutide) produce a characteristic CGM pattern: modest fasting glucose reduction paired with a pronounced flattening of postprandial spikes. The mechanism is dual. First, GLP-1 RAs slow gastric emptying, stretching glucose absorption over a longer window. Second, they potentiate glucose-dependent insulin secretion, capping the spike height.

In the STEP-1 trial (N=1,961), once-weekly semaglutide 2.4 mg reduced body weight by 14.9% at 68 weeks versus 2.4% on placebo (4). CGM sub-studies of semaglutide consistently show that 2-hour postprandial glucose drops by 30 to 50 mg/dL within the first 4 weeks of dose escalation.

What a GLP-1 RA Looks Like on a 14-Day CGM Report

The ambulatory glucose profile (AGP) for a patient starting semaglutide typically shows:

• Meal spikes that were previously 180 to 220 mg/dL falling to 140 to 160 mg/dL.
• The interquartile range (the shaded band on the AGP) narrowing, reflecting lower CV.
• Fasting glucose dropping by 10 to 20 mg/dL, usually within 2 to 4 weeks of reaching a stable dose.

Because GLP-1 RAs are glucose-dependent, they carry minimal hypoglycemia risk as monotherapy. Time-below-range (TBR) below 70 mg/dL should remain near zero. If a patient's CGM shows repeated TBR episodes after starting a GLP-1 RA, the most likely culprit is a concurrent sulfonylurea or insulin dose that has not been down-titrated.

Tirzepatide vs. Semaglutide: CGM Differences

Tirzepatide (GIP/GLP-1 dual agonist) produces larger mean glucose reductions than semaglutide at equipotent doses. The SURPASS-2 trial (N=1,879) showed tirzepatide 15 mg reduced A1C by 2.46 percentage points versus 2.09 for semaglutide 1 mg at 40 weeks (5). On CGM, tirzepatide tends to reduce MSG by an additional 8 to 15 mg/dL compared with semaglutide, with a correspondingly larger improvement in TIR.

Metformin: Subtle but Consistent CGM Changes Over Weeks

Metformin does not produce dramatic CGM shifts visible on a single day's trace. Its mechanism (primarily hepatic glucose production suppression) lowers fasting glucose by 20 to 30 mg/dL over 8 to 12 weeks rather than within hours. The UKPDS 34 study showed metformin reduced A1C by approximately 0.6 to 1.5 percentage points in overweight patients with type 2 diabetes (6).

On CGM, the metformin signature is a gradual leftward shift of the entire glucose distribution, fasting drops first, postprandial peaks narrow modestly. Hypoglycemia risk is negligible; TBR should stay at zero.

Why Metformin's CGM Effect Is Easy to Miss

Because the changes accumulate over weeks, a single 10-day CGM sensor worn at metformin initiation will not capture the full effect. Clinicians should compare a sensor worn at week 0 with one worn at week 8 to 12 to see the true delta. Patients who stop metformin abruptly will see fasting glucose creep up by 15 to 25 mg/dL within 5 to 7 days.

SGLT2 Inhibitors: Fasting Glucose Reduction With an Unexpected Safety Floor

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) block renal glucose reabsorption, excreting roughly 60 to 80 grams of glucose per day in the urine. Their CGM fingerprint is a consistent reduction in fasting glucose of 20 to 30 mg/dL and a modest blunting of postprandial excursions.

The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced A1C by 0.54 percentage points versus placebo and reduced cardiovascular death by 38% (7). CGM data from mechanistic sub-studies confirm that the glucose-lowering effect is present within 48 to 72 hours of the first dose.

Time-Below-Range Risk With SGLT2 Inhibitors

As monotherapy, SGLT2 inhibitors rarely cause hypoglycemia because their action is glycosuria-dependent (the drug stops excreting glucose when plasma levels fall below the renal threshold of roughly 180 mg/dL). However, when combined with insulin or sulfonylureas, the additive glucose lowering can push TBR above 4%. The ADA Standards 2024 recommend reducing insulin doses by 10 to 20% when initiating an SGLT2 inhibitor in a patient already on insulin (3).

The Euglycemic DKA Signal on CGM

Patients on SGLT2 inhibitors who develop diabetic ketoacidosis (DKA) may show CGM glucose values in the 130 to 180 mg/dL range, well within what appears to be normal range. This "euglycemic DKA" pattern is a known SGLT2 inhibitor risk. Clinicians should not rely on CGM glucose values alone to rule out DKA; serum or urine ketones are required when symptoms appear (8).

Insulin: The Strongest CGM Effect, the Highest Hypoglycemia Risk

Insulin therapy produces the largest absolute improvement in TIR of any drug class, but it also carries the highest risk of TBR events. The CGM trace after basal insulin initiation (glargine, detemir, degludec) typically shows a falling fasting glucose that stabilizes after 3 to 7 days of dose titration.

The BRIGHT trial (N=929) compared insulin glargine 300 U/mL versus insulin degludec 100 U/mL. Both arms achieved similar A1C reductions (approximately 1.6 percentage points), but degludec showed fewer hypoglycemia events during weeks 1 to 8 (9). On CGM, degludec's longer half-life produces a smoother fasting glucose trajectory with lower overnight TBR.

Reading a Rapid-Acting Insulin Response on CGM

Rapid-acting analogs (lispro, aspart, glulisine) act within 15 minutes and peak at 60 to 90 minutes. On the CGM trace, a well-dosed meal bolus produces a post-meal spike capped at or below 180 mg/dL, with glucose returning to baseline within 3 hours. An over-bolused patient will show a post-meal dip below 70 mg/dL at the 2-to-3-hour mark.

The 1500 Rule (or 1800 Rule for more insulin-sensitive patients) estimates how much 1 unit of rapid-acting insulin drops plasma glucose. Dividing 1700 by total daily insulin dose gives an approximate insulin sensitivity factor in mg/dL per unit. CGM makes this calculation iterative and far more precise than A1C-based adjustments.

Closed-Loop Systems and CGM Integration

Automated insulin delivery (AID) systems use CGM data as their primary input. The landmark CLOSED trial and the DIaMonD closed-loop studies both demonstrated that AID improves TIR by 10 to 15 percentage points versus sensor-augmented pump therapy alone (10). The CGM is not merely a monitoring tool in these systems; it is the control input.

Corticosteroids: The Most Dramatic and Predictable CGM Pattern

Corticosteroids (prednisone, dexamethasone, methylprednisolone) cause a characteristic afternoon/evening glucose surge. Morning dosing of prednisone (the most common regimen) drives hepatic glucose output and peripheral insulin resistance, with peak glucose elevation occurring 4 to 8 hours post-dose. On a CGM ambulatory glucose profile, this shows up as a steep rise in the afternoon and evening, with near-normal fasting values in the early morning.

A patient on 40 mg prednisone daily may see postprandial glucose values exceeding 250 to 300 mg/dL even without a prior diabetes diagnosis. The PRECISION-Dex study and several single-center cohorts confirm that steroid-induced hyperglycemia affects 20 to 50% of hospitalized non-diabetic patients receiving high-dose corticosteroids (11).

Matching Insulin Regimen to the Corticosteroid CGM Pattern

Because the hyperglycemia is postprandial and afternoon-dominant, basal insulin alone is often insufficient. NPH insulin (intermediate-acting, peak 4 to 8 hours) given with the morning prednisone dose has long been used to match the steroid's glucose-raising curve. CGM makes this matching visible in real time; the clinician can see whether the NPH dose is blunting the afternoon spike or whether a rapid-acting bolus is also needed.

Other Medications With Clinically Significant CGM Effects

Several other drug classes alter CGM readings in ways that clinicians may not anticipate.

Fluoroquinolone Antibiotics

Fluoroquinolones (ciprofloxacin, levofloxacin) can cause both hypoglycemia and hyperglycemia by altering pancreatic beta-cell potassium channel activity. The FDA added a boxed warning for dysglycemia in 2018 (12). Patients on fluoroquinolones should be counseled that their CGM may show unexplained excursions in either direction during a 5-to-10-day course.

Atypical Antipsychotics

Olanzapine, clozapine, and quetiapine increase insulin resistance and drive weight gain, producing a gradual upward drift in fasting CGM values over months. A meta-analysis of 17 trials (N=1,968) found that atypical antipsychotics raised fasting glucose by an average of 5.8 mg/dL compared with typical antipsychotics or placebo (13).

Acetaminophen and CGM Sensor Interference

Acetaminophen at doses above 1 gram can falsely raise electrochemical CGM sensors (notably the Dexcom G6) by oxidizing at the sensor electrode and being misread as glucose. The Dexcom G6 labeling states that acetaminophen at 1 g every 6 hours may cause falsely elevated readings (14). The Abbott Freestyle Libre 3 uses a different enzymatic chemistry with lower acetaminophen susceptibility.

What Is the Optimal CGM Range?

The "normal" CGM range and the "optimal" CGM range are different targets, and the right target depends on the clinical context.

Diabetes Management Targets

The ADA Standards of Care 2024 and the joint ADA/EASD consensus on CGM metrics set the following targets for most adults with type 1 or type 2 diabetes (3):

• TIR (70 to 180 mg/dL): above 70% of readings.
• Time above range (TAR, above 180 mg/dL): below 25%.
• TBR (below 70 mg/dL): below 4%.
• TBR (below 54 mg/dL): below 1%.

Each 10% improvement in TIR corresponds to a roughly 0.5 percentage-point drop in A1C, based on data from the CGM validation studies pooled by Šoupal et al. (N=200, CGM + A1C correlation) (15).

Longevity and Metabolic Optimization Targets

In non-diabetic adults using CGM for preventive or metabolic optimization purposes, the evidence base is thinner but a working consensus is emerging. Levels Health and several longevity-medicine practitioners cite post-meal glucose targets of below 140 mg/dL (1-hour) and below 120 mg/dL (2-hour), with mean sensor glucose ideally below 110 mg/dL. A 2023 observational study of CGM use in non-diabetic adults (N=153) found that mean glucose above 100 mg/dL was associated with higher visceral adiposity and higher HOMA-IR, independent of BMI (16).

The HealthRX clinical team uses the following three-tier CGM target framework for non-diabetic patients on metabolic optimization protocols:

• Tier 1 (minimum acceptable): TIR 70 to 140 mg/dL above 80%, MSG below 120 mg/dL, CV below 36%.
• Tier 2 (good metabolic control): TIR 70 to 120 mg/dL above 65%, post-meal spikes below 140 mg/dL, no readings below 70 mg/dL.
• Tier 3 (optimal longevity target): MSG below 100 mg/dL, post-meal excursion delta below 30 mg/dL, CV below 20%.

These tiers are a clinical decision tool. They do not replace individualized clinical judgment and are not ADA-endorsed targets.

Interpreting a CGM Report After Starting a New Medication: A Practical Framework

Reading a CGM ambulatory glucose profile after a drug change requires a structured approach. Jumping to conclusions from a single day's trace leads to premature dose adjustments.

Minimum Sensor Wear Before Drawing Conclusions

At minimum, 10 days of continuous wear are needed to generate a statistically stable AGP. The ATTD consensus statement specifies that 70% of possible readings (10 of 14 days for a biweekly sensor) is the minimum data completeness for reliable TIR reporting (2). Starting a new sensor on the same day as a new drug also introduces a calibration warm-up artifact in the first 24 hours; ideally, start the sensor 48 hours before the new drug.

Matching Drug Pharmacokinetics to the CGM Time Scale

| Drug Class | Onset of CGM-Visible Effect | Full CGM Effect | |---|---|---| | Rapid-acting insulin | 15 to 30 minutes | Single meal | | SGLT2 inhibitor | 48 to 72 hours | 2 to 4 weeks | | GLP-1 RA (weekly) | 4 to 7 days | 8 to 12 weeks | | Metformin | 1 to 2 weeks | 8 to 12 weeks | | Corticosteroid | Hours | Dose-dependent | | Atypical antipsychotic | Weeks to months | Months |

Red Flags on a CGM Report That Require Same-Day Clinical Review

• Any reading below 54 mg/dL, particularly overnight (2:00 to 4:00 AM).
• TAR above 180 mg/dL exceeding 50% of readings in the first week on a new medication.
• CV above 50% suggesting erratic glycemic swings.
• A flat trace in a patient on insulin (may indicate sensor failure or severe insulin resistance masking hypoglycemia).

CGM Accuracy Limitations That Affect Medication Monitoring

No CGM is perfectly accurate. Mean absolute relative difference (MARD) values for current-generation sensors range from 8.2% (Dexcom G7) to 9.4% (Abbott Libre 3), both measured against venous glucose reference standards in key trials (17). A MARD of 9% means a true glucose of 100 mg/dL might read as 91 or 109 mg/dL.

For medication management, the practical implication is that CGM readings should never be used to dose insulin in a patient who is symptomatic for hypoglycemia without a confirmatory fingerstick. The ADA Standards 2024 reiterate this point specifically: CGM readings should be confirmed with blood glucose meters before treatment decisions in symptomatic patients (3).

Critically ill patients, patients with severe edema, and patients using high-dose vitamin C (above 500 mg/day) may also experience CGM inaccuracy above the validated MARD thresholds.